• NYSE Regulation accepted Oragenics' compliance plan Nov. 11, 2026, granting until Feb. 25, 2028, to regain compliance with listing standards.
• Shares will remain listed on NYSE American during the compliance period, subject to plan milestones and ongoing reviews.
• The Aug. 26, 2026, deficiency notice cited stockholders' equity of $3.7 million as of June 30, 2026.
• Noncompliance also reflected losses from continuing operations and/or net losses in the five fiscal years ended Dec. 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oragenics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121600PRIMZONEFULLFEED9876741) on November 12, 2026, and is solely responsible for the information contained therein.